Data from The lncRNA <i>PCAT29</i> Inhibits Oncogenic Phenotypes in Prostate Cancer

Abstract

<div>Abstract<p>Long noncoding RNAs (lncRNA) have recently been associated with the development and progression of a variety of human cancers. However, to date, the interplay between known oncogenic or tumor-suppressive events and lncRNAs has not been well described. Here, the novel lncRNA, prostate cancer–associated transcript 29 (<i>PCAT29</i>), is characterized along with its relationship to the androgen receptor. <i>PCAT29</i> is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model. <i>PCAT29</i> knockdown significantly increased proliferation and migration of prostate cancer cells, whereas <i>PCAT29</i> overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. Finally, in prostate cancer patient specimens, low <i>PCAT29</i> expression correlated with poor prognostic outcomes. Taken together, these data expose <i>PCAT29</i> as an androgen-regulated tumor suppressor in prostate cancer.</p><p><b>Implications:</b> This study identifies <i>PCAT29</i> as the first androgen receptor–repressed lncRNA that functions as a tumor suppressor and that its loss may identify a subset of patients at higher risk for disease recurrence.</p><p><b>Visual Overview:</b> <a href="http://mcr.aacrjournals.org/content/early/2014/07/31/1541-7786.MCR-14-0257/F1.large.jpg" target="_blank">http://mcr.aacrjournals.org/content/early/2014/07/31/1541-7786.MCR-14-0257/F1.large.jpg</a>. <i>Mol Cancer Res; 12(8); 1081–7. ©2014 AACR</i>.</p></div>